TPX2 and hepatocellular carcinoma: The presence of TPX2 was found to trigger accelerated metabolism or clearance of sorafenib, a typical tyrosine kinase inhibitor (TKI), in hepatocellular carcinoma (HCC), leading to resistance of HCC cells to sorafenib (Wang et al., 2023).